Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis.

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL BioMedicine-Taiwan Pub Date : 2024-03-01 eCollection Date: 2024-01-01 DOI:10.37796/2211-8039.1429
Soulandi Djorwé, Amale Bousfiha, Néhémie Nzoyikorera, Joseph Nyandwi, Bellamine Kawthar, Abderrahim Malki
{"title":"Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis.","authors":"Soulandi Djorwé, Amale Bousfiha, Néhémie Nzoyikorera, Joseph Nyandwi, Bellamine Kawthar, Abderrahim Malki","doi":"10.37796/2211-8039.1429","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 patients usually present multiple comorbidities and complications associated with severe forms of SARS-CoV-2 infection. This study aimed to assess the risk factors and prevalence of comorbidities and complications contributing to the severity of COVID-19.</p><p><strong>Methods: </strong>This meta-analysis was performed according to PRISMA guidelines. We searched various databases, including PubMed, Google Scholar, and Scopus (between 2020 and 2023), for eligible studies for this meta-analysis.</p><p><strong>Results: </strong>Thirty-three studies were eligible, including 85,812 patients, of which 36 % (30,634/85,812) had severe disease, whereas 64 % (55,178/85,812) had non-severe disease. Severe cases were potentially correlated with the following factors: gender (male) (odd ratio (OR) = 1.52, 95 % CI: 1.34-1.73), advanced age (OR = 3.06, 95 % CI: 2.18-4.40) pre-existing smoking (OR = 1.33, 95 % CI: 1.01-1.75), obesity (OR = 2.11, 95 % CI: 1.47-3.04), diabetes (OR = 1.81, 95 % CI: 1.35-2.43), hypertension (OR = 2.22, 95 % CI: 1.72-2.87), coronary heart disease (OR = 2.17, 95 % CI: 1.42-3.31), CKD (OR = 2.27, 95 % CI: 1.26-4.06), COPD (OR = 1.95, 95 % CI: 1.22-3.09), malignancy (OR = 1.63, 95 % CI: 1.07-2.49) and cerebrovascular disease (OR = 2.76, 95 % CI: 1.63-4.62). All these comorbidities were significantly higher in the severe COVID-19 group compared with the non-severe COVID-19 group. In addition, the most severe complications were associated with shock (OR = 28.08, 95 % CI: 3.49-226.03), ARDS (OR = 13.09, 95 % CI: 5.87-29.18), AKI (OR = 16.91, 95 % CI: 1.87-152.45) and arrhythmia (OR = 7.47, 95 % CI: 2.96-18.83). However, these complications were the most likely to prevent recovery in patients with severe affections compared with non-severe affection groups.</p><p><strong>Conclusion: </strong>All the comorbidities and complications listed above are more likely to cause severe forms of COVID-19 in some patients and hinder recovery. They are therefore risk factors to be controlled to minimize the undesirable effects of the disease.</p>","PeriodicalId":51650,"journal":{"name":"BioMedicine-Taiwan","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962561/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioMedicine-Taiwan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37796/2211-8039.1429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 patients usually present multiple comorbidities and complications associated with severe forms of SARS-CoV-2 infection. This study aimed to assess the risk factors and prevalence of comorbidities and complications contributing to the severity of COVID-19.

Methods: This meta-analysis was performed according to PRISMA guidelines. We searched various databases, including PubMed, Google Scholar, and Scopus (between 2020 and 2023), for eligible studies for this meta-analysis.

Results: Thirty-three studies were eligible, including 85,812 patients, of which 36 % (30,634/85,812) had severe disease, whereas 64 % (55,178/85,812) had non-severe disease. Severe cases were potentially correlated with the following factors: gender (male) (odd ratio (OR) = 1.52, 95 % CI: 1.34-1.73), advanced age (OR = 3.06, 95 % CI: 2.18-4.40) pre-existing smoking (OR = 1.33, 95 % CI: 1.01-1.75), obesity (OR = 2.11, 95 % CI: 1.47-3.04), diabetes (OR = 1.81, 95 % CI: 1.35-2.43), hypertension (OR = 2.22, 95 % CI: 1.72-2.87), coronary heart disease (OR = 2.17, 95 % CI: 1.42-3.31), CKD (OR = 2.27, 95 % CI: 1.26-4.06), COPD (OR = 1.95, 95 % CI: 1.22-3.09), malignancy (OR = 1.63, 95 % CI: 1.07-2.49) and cerebrovascular disease (OR = 2.76, 95 % CI: 1.63-4.62). All these comorbidities were significantly higher in the severe COVID-19 group compared with the non-severe COVID-19 group. In addition, the most severe complications were associated with shock (OR = 28.08, 95 % CI: 3.49-226.03), ARDS (OR = 13.09, 95 % CI: 5.87-29.18), AKI (OR = 16.91, 95 % CI: 1.87-152.45) and arrhythmia (OR = 7.47, 95 % CI: 2.96-18.83). However, these complications were the most likely to prevent recovery in patients with severe affections compared with non-severe affection groups.

Conclusion: All the comorbidities and complications listed above are more likely to cause severe forms of COVID-19 in some patients and hinder recovery. They are therefore risk factors to be controlled to minimize the undesirable effects of the disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
合并症和并发症对 COVID-19 严重程度的影响和发生率与年龄、性别、肥胖和原有吸烟情况的关系:荟萃分析。
背景:COVID-19患者通常伴有多种合并症和并发症,与严重的SARS-CoV-2感染相关。本研究旨在评估导致 COVID-19 严重程度的合并症和并发症的风险因素和患病率:本荟萃分析根据 PRISMA 指南进行。我们检索了各种数据库,包括 PubMed、Google Scholar 和 Scopus(2020 年至 2023 年),寻找符合荟萃分析条件的研究:符合条件的研究有 33 项,包括 85,812 名患者,其中 36% (30,634/85,812)的患者病情严重,而 64% (55,178/85,812)的患者病情不严重。重症病例可能与以下因素有关:性别(男性)(奇数比 (OR) = 1.52,95 % CI:1.34-1.73)、高龄(OR = 3.06,95 % CI:2.18-4.40)、吸烟(OR = 1.33,95 % CI:1.01-1.75)、肥胖(OR = 2.11,95 % CI:1.47-3.04)、糖尿病(OR = 1.81,95 % CI:1.35-2.43)、高血压(OR = 2.22,95 % CI:1.72-2.87)、冠心病(OR = 2.17,95 % CI:1.42-3.31)、慢性肾脏病(OR = 2.27,95 % CI:1.26-4.06)、慢性阻塞性肺病(OR = 1.95,95 % CI:1.22-3.09)、恶性肿瘤(OR = 1.63,95 % CI:1.07-2.49)和脑血管疾病(OR = 2.76,95 % CI:1.63-4.62)。与非重度 COVID-19 组相比,重度 COVID-19 组的所有这些并发症发生率都明显较高。此外,最严重的并发症与休克(OR = 28.08,95 % CI:3.49-226.03)、ARDS(OR = 13.09,95 % CI:5.87-29.18)、AKI(OR = 16.91,95 % CI:1.87-152.45)和心律失常(OR = 7.47,95 % CI:2.96-18.83)有关。然而,与非严重影响组相比,这些并发症最有可能阻碍严重影响组患者的康复:结论:上述所有合并症和并发症在某些患者中更有可能导致严重的 COVID-19 并阻碍康复。因此,应控制这些风险因素,以尽量减少疾病的不良影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BioMedicine-Taiwan
BioMedicine-Taiwan MEDICINE, GENERAL & INTERNAL-
CiteScore
2.80
自引率
5.90%
发文量
21
审稿时长
24 weeks
期刊最新文献
Comparative analysis of Doxycycline and Ayurvedic herbs to target metastatic breast cancer: An in-silico approach. Glutaminase - A potential target for cancer treatment. Phytochemical composition of Clinacanthus nutans based on factors of environment, genetics and postharvest processes: A review. Protection of Gueichih-Fuling-Wan on cerebral ischemia-induced brain injury in rodents is mediated by trans-cinnamaldehyde via inhibition of neuroinflammation and apoptosis. Unveiling the power of flavonoids: A dynamic exploration of their impact on cancer through matrix metalloproteinases regulation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1